ValuEngine Lowers American Renal Associates (NYSE:ARA) to Buy

Share on StockTwits

American Renal Associates (NYSE:ARA) was downgraded by stock analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday, ValuEngine reports.

Separately, SunTrust Banks raised their price objective on American Renal Associates from $7.00 to $12.00 and gave the stock a “hold” rating in a research note on Tuesday, September 10th. Seven investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $11.25.

Shares of American Renal Associates stock opened at $9.49 on Thursday. American Renal Associates has a 12 month low of $5.48 and a 12 month high of $17.31. The company has a quick ratio of 0.97, a current ratio of 1.01 and a debt-to-equity ratio of 8.05. The stock’s fifty day simple moving average is $7.35 and its 200 day simple moving average is $7.17.

American Renal Associates (NYSE:ARA) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.33 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.37. The business had revenue of $211.43 million for the quarter, compared to the consensus estimate of $215.06 million. American Renal Associates had a positive return on equity of 23.16% and a negative net margin of 1.75%. As a group, research analysts anticipate that American Renal Associates will post -0.68 earnings per share for the current year.

Institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its holdings in shares of American Renal Associates by 347.3% in the 3rd quarter. Tower Research Capital LLC TRC now owns 8,705 shares of the company’s stock worth $55,000 after acquiring an additional 6,759 shares during the last quarter. California Public Employees Retirement System raised its holdings in shares of American Renal Associates by 7.0% in the 3rd quarter. California Public Employees Retirement System now owns 91,266 shares of the company’s stock worth $577,000 after acquiring an additional 5,946 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of American Renal Associates in the 2nd quarter worth about $233,000. Marshall Wace LLP raised its holdings in shares of American Renal Associates by 715.2% in the 2nd quarter. Marshall Wace LLP now owns 92,039 shares of the company’s stock worth $684,000 after acquiring an additional 80,748 shares during the last quarter. Finally, Morgan Stanley raised its holdings in shares of American Renal Associates by 68.5% in the 2nd quarter. Morgan Stanley now owns 5,932 shares of the company’s stock worth $44,000 after acquiring an additional 2,412 shares during the last quarter. 86.12% of the stock is currently owned by institutional investors and hedge funds.

About American Renal Associates

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Featured Story: Convertible Shares

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.